Sangamo Therapeutics Inc — Cash Flow (NASDAQ:SGMO) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities 169.88 M-233.25 M-223.63 M-224.84 M-67.14 M-97.21 M -97.21 M Cash from investing activities -271.63 M248.2 M59.28 M153.53 M37.52 M-102 K -102 K Cash from financing activities 153.1 M32.86 M84.66 M14.59 M28.38 M70.75 M 70.75 M Free cash flow 155.16 M-256.53 M-243.8 M-246 M-67.41 M-97.31 M -97.29 M

Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.

Haberler

Sangamo Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SGMO) 2026-04-02

Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript

Sangamo’nun 4Ç 2025 kazancı beklentileri karşılamadı

Sangamo Therapeutics kazancı $0,10 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26 - TipRanks.com

IVV vs. ITOT vs. IWM: Which iShares ETF Could Deliver the Best Returns in 2026? - TipRanks.com

Sangamo Therapeutics, Inc. (SGMO) Presents at 22nd Annual WORLDSymposium - Slideshow (NASDAQ:SGMO) 2026-02-04

Sangamo gen terapisi, Fabry hastalığında olumlu böbrek fonksiyonu sonuçları gösterdi

Sangamo gene therapy shows positive kidney function results in Fabry disease